Related Experiment Videos
Breast cancer screening: using familiality for earlier detection
R P R Groenendijk1, M C Rombouts, T J M Ruers
1Department of Surgery, IJsselland Hospital, Capelle a/d IJssel, The Netherlands. rgroenendijk@ysl.nl
Breast (Edinburgh, Scotland)
|February 18, 2004
Summary
A positive family history of breast cancer does not influence early detection or improve patient survival. This study found no significant differences in tumor stage or prognostic markers between patients with and without a family history of breast cancer.
Area of Science:
- Oncology
- Genetics
- Epidemiology
Background:
- Family history is a known risk factor for breast cancer.
- Genetic predisposition may influence tumor characteristics and prognosis.
Purpose of the Study:
- To determine if breast cancer in patients with a positive family history is detected earlier and has better prognostic markers compared to those without.
- To investigate the impact of first-degree versus second-degree relatives with breast cancer on detection stage and survival.
Main Methods:
- Retrospective analysis of 481 breast cancer patients.
- Comparison of tumor size, type, invasion (lymphatic/blood vessel), receptor status, lymphatic spread, mitotic activity index (MAI), and survival based on family history.
- Stratification by presence and degree of family history (none, first-degree, second-degree relatives).
Main Results:
- No significant differences were observed in tumor detection stage across all family history groups.
- Prognostic factors, including MAI and survival rates, were similar for patients with and without a family history of breast cancer.
- No distinction in outcomes was found between patients with first-degree versus second-degree relatives diagnosed with breast cancer.
Conclusions:
- A positive family history of breast cancer does not correlate with earlier detection.
- Family history does not appear to influence prognostic markers or survival outcomes in breast cancer patients.
- Genetic predisposition, as indicated by family history, may not alter the clinical presentation or prognosis of breast cancer in this cohort.